Ultragenyx expects continued global revenue growth in 2025, underpinned by the expansion of existing therapies and the anticipated commercialization of new products such as UX111 and DTX401.

The regions include the European Economic Area. The collaboration with Regeneron for Evkeeza gives Ultragenyx a fourth-approved product that adds to the top line. However, REGN solely ...

Arizona State Retirement System boosted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 2.4% in the 4th quarter, according to its most recent filing with the Securities ...

Smartleaf Asset Management LLC increased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 259.5% during the fourth quarter, according to its most recent filing ...

Learn more about whether Kymera Therapeutics, Inc. or Ultragenyx Pharmaceutical Inc. is a better investment based on AAII's ...

and the availability or commercial potential of Ultragenyx’s products and drug candidate. Ultragenyx undertakes no obligation to update or revise any forward-looking statements. For a further ...

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse ...

Ultragenyx has established itself as a key player in the rare disease space, with a portfolio of approved products and a robust pipeline of candidates in various stages of development. The company's ...